Opinion
Video
Author(s):
The relapsed/refractory multiple myeloma experts conclude by highlighting current unmet needs in the field and sharing valuable clinical pearls to guide practice and improve patient outcomes.
Tapotoclax Demonstrates Safety, Yields Anti-Leukemic Effects but No Responses in MDS Following HMAs
Garcia-Manero on MDS Treatment Updates With Luspatercept and Beyond
Subcutaneous Daratumumab Quadruplet Approaches EU Approval for Newly Diagnosed Myeloma
FDA Approval Insights: Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer
FDA Grants RMAT Designation to P-BCMA-ALL01 for R/R Multiple Myeloma
Belantamab Mafodotin Plus Vd Earns Breakthrough Therapy Designation in China for R/R Myeloma
NKT2152 Data Reinforce the Importance of HIF2α Inhibition in Advanced Clear Cell RCC
CheckMate-9ER Post-Hoc Analysis Seeks to Identify Efficacy Biomarkers for Nivolumab/Cabozantinib in RCC
Elacestrant Plus Abemaciclib Demonstrates Clinical Benefit in Pretreated ER+/HER2– Metastatic Breast Cancer
Experts Highlight Top Findings From the 2024 IASLC World Conference on Lung Cancer